Weekly Digest – April 2025 Weekly Digest – April 2025 10 Apr 2025: IDEAYA Biosciences announces Phase 1/2 expansion for IDE397 and Trodelvy combination in MTAP-deletion urothelial cancer IDEAYA Biosciences has begun a Phase 1/2 trial of a MAT2A inhibitor, […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: Novelty Nobility, selected by JLABS Korea, hosted by Johnson & Johnson Novelty Nobility has joined JLABS Korea, Johnson & Johnson’s global incubator network, to accelerate its antibody […]
Weekly Digest – April 2025 Weekly Digest – April 2025 09 Apr 2025: OS Therapies completes acquisition of Advaxis Immunotherapies clinical, pre-clinical and IP assets from Ayala Pharmaceuticals OS Therapies (NYSE-A: OSTX) has completed the acquisition of listeria-based cancer immunotherapy […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO DualityBio has officially launched its IPO in Hong Kong, aiming to raise up to $200 […]
Weekly Digest – April 2025 Weekly Digest – April 2025 04 Apr 2025: Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic Breast cancer following at least one endocrine therapy The European […]
Weekly Digest – April 2025 Weekly Digest – April 2025 31 Mar 2025: TIVDAK (Tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic Cervical cancer The European Commission has approved TIVDAK (Tisotumab vedotin) as the first and […]
Weekly Digest – April 2025 Weekly Digest – April 2025 02 Apr 2025: Mabwell announces NMPA approval to initiate clinical trial of novel B7-H3-targeting ADC for advanced solid tumors in combination with PD-1 inhibitor Mabwell’s novel B7-H3-targeting ADC, 7MW3711, has […]
Weekly Digest – April 2025 Weekly Digest – April 2025 31 Mar 2025: SPARC announces submission of IND application for SBO-154 to USFDA SPARC submitted an Investigational New Drug (IND) application to the US FDA on March 31, 2025, for […]
Weekly Digest – April 2025 Weekly Digest – April 2025 01 Apr 2025: OBI has submitted the IND application of a Phase 1/2 human clinical trial for OBI-902 TROP2 ADC to the US FDA OBI Pharma submitted an Investigational New […]
Weekly Digest – April 2025 Weekly Digest – April 2025 03 Apr 2025: Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D centre in Basel Boehringer Ingelheim has invested $31 million to establish a new antibody-drug conjugate (ADC) […]
